Glycogen Storage Disease in Pediatric Population

Autor: Marium Mohammed Iqbal, Maram Mohammed Bajoaifur, Atheer Eed Alotaibi, Mohammed Younes Almoghrabi, Emtenan Abed Al Ansari, Fahad Abdulaziz Jarad, Huda F. Abbag, Saad Mahmoud Tobaigi, Mohammad Abdullah Alotaibi, Bayan Sultan Al Jobran, Hadil Mohammed Alenezi, Wejdan Hamed Alshammari, Badoor Abdrabalameer Alghafli, Reem Ali Almanie, Faris Abdullah S Alharbi, Amro Sulaiman AlJuhani, Yara Mofarih Assiri, Ashwaq Y. Asiri
Rok vydání: 2018
Předmět:
Zdroj: The Egyptian Journal of Hospital Medicine. 70:1539-1543
ISSN: 2090-7125
1687-2002
DOI: 10.12816/0044680
Popis: Introduction: The pathway of glycogen metabolism is regulated by many hormones such as insulin, glucagon, and corticosteroids. Glycogen storage diseases (GSD) most commonly affect muscles, liver, or both and occur in each 20000 to 43000 live birth. They are classified into 12 subtypes, but types I, II, and IX are the most common. Methodology: We conducted this review using a comprehensive search of MEDLINE, PubMed, and EMBASE, from January 2001, through February 2017. The following search terms were used: glycogen storage diseases, Von Gierke disease, Pompe’s disease, Cori Disease, Forbes disease, Andersen’s disease, McArdle disease, neonatal hypoglycemia, neonatal hepatomegaly. Aim: In this review, we aim to study the genetic basis, diagnosis, presentation, and different management approach to various common types of glycogen storage diseases prevalent in pediatric population. Conclusion: There are no cures for any type of glycogen storage diseases presently. Most treatments are designed to control signs and symptoms. The overall goals are primarily avoiding hypoglycemia, hyperlactatemia, hyperuricemia, and hyperlipidemia. Liver transplantation should be deliberated for patients with GSD type IV and for other progressive hepatic types of GSDs in order to avoid hepatic failure or malignancy. More research must be carried out to develop newer and more effective ways of management.
Databáze: OpenAIRE